Antiretroviral therapy: 'The state of the art'

Biomedicine and Pharmacotherapy

Volumn 53, Issue 2, 1999, Pages 63-72

  Montaner, J S G ^a   Montessori, V ^a   Harrigan, R ^a   O'Shaughnessy, M ^a   Hogg, R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

AIDS; Antiretroviral therapy; HIV

Indexed keywords

ABACAVIR; ADEFOVIR DIPIVOXIL; AMPRENAVIR; ANTIRETROVIRUS AGENT; CARNITINE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMIVIRINE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ADVERSE DRUG REACTION; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

EID: 0033102481     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(99)80062-6     Document Type: Article

References (41)

1. 1 Arribas JR, Gonzalez-Garcia J, Ibanez C, Ruiz B, Peña JM, Esteban C, et al. Acute hepatitis in AIDS patients during ritonavir treatment [Abstract 417]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
2. - counts > 400 cells/μl and viral load > 5,000 copies/mL [Abstract 365]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
3. 3 Beach RS, Wohlfeiler MB, Silva A. Indinavir/Nevirapine combination therapy in advanced HIV-1 infection [Abstract 428]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
4. 4 Borleffs JC on behalf of the CHEESE Study Team. First comparative study of saquinavir soft gel capsules versus indinavir as part of triple therapy regimen (CHEESE) [Abstract 387b]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
5. 5 Bouhamdan M. Duan LX. Pomerantz RJ. Inhibition of human immunodeficiency virus type A replication by expression of fusion protein, vpr-single-chain anti-integrase [Abstract 644]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
6. 6 Cameron DW, Japour A, Mellors J, Farthing C, Cohen C, Markowitz M, et al. Antiretroviral safety and durability of ritonavir-saquinavir in protease inhibitor-naive patients in year two of follow-up [Abstract 388]. 5th Conference on Retroviruses and Opportunistic Infections, 1998.
7. 7 Carpenter, CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1997 : updated recommendations of the International AIDS Society-USA Panel. JAMA 1997; 277 (24) : 1962-9.
8. 8 Casano P, Hermans P, Sommereijns, B, de Wit S, Kabeya K, O'Doherty E, et al. Combined quadruple therapy with ritonavir-saquinavir + nucleosides in patients who failed triple therapy with RTV, SQV or Indinavir [Abstract 423]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
9. 9 CAESAR Coordinating Committee. Randomized trial of addition of lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349 : 1413-21.
10. 10 Cohen CJ, Hellinger JA, Stein AJ, Gathe J, Reiser P. Can Nelfinavir substitute for other protease inhibitor(s) in persons with plasma HIV-1 RNA below 500 copies/mL before the substitution? [Abstract 387]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
11. + T-cell changes in patients failing potent protease inhibitor therapy [Abstract 419]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
12. 12 Deeks S, Loftus R, Cohen P, Chin S, Grant R. Incidence and predictors of virologie failure to indinavir and/or ritonavir in an urban health clinic [Abstract LB-2]. 37th ICAAC; 1997.
13. 13 Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Panel on clinical practices for treatment of HIV infection; 1997.
14. 14 Eron J, Haubrich R, Richman D, Lang W, Tisdale M, Myers R, et al. Preliminary assessment of 141W94 in combination with other protease inhibitors [Abstract 6]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
15. 15 Gallant JE, Hall C, Barnett S. Raines C. Ritonavir/saquinavir as salvage therapy after failure of initial protease inhibitor regimen [Abstract 427]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
16. 16 Gallant JE, Heath-Chiozzi M, Raines C, Anderson R, Katz T, Fields C, et al. Safety and efficacy of nelfinavir-ritonavir combination Therapy [Abstract 394-A]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
17. 17 Gerard M, de Wit S, Sprecher S, de Cock F, Van Laethem Y, Hermans P, et al. Salvage anti HIV triple therapy with foscarnet in combination with nelfinavir and nevirapine in heavily pretreated patients [Abstract 424]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
18. 18 Harris M, Whaley M, de Wet JJ, Raboud J, Rac S, Conway B, et al. One year follow-up of HIV patients treated with nevirapine, indinavir and lamivudine [Abstract 429a]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
19. 19 Havlir DV, Friedland G, Pollard R, Tierney C, Smeaton L, Fox L, et al. Combination zidovudine (ZDV) and stavudine (d4T) therapy versus other nucleosides: report of two randomized trials (ACTG 290 and 298) [Abstract 2]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
20. 20 Havlir DV, Riddler S, Squires K, Winslow D, Kerr B, Nguyen BY, et al. Co-administration of indinavir (IDV) and nelfinavir (NFV) in a twice daily regimen: Preliminary safety, pharmacokinetic and anti-viral activity results [Abstract 393]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
21. 21 Hazelwood D, Koel JL, Nail CD, Marangos M, Smith R, Miles S, et al. Multi-drug resistant HIV-1 isolates from patients with rising plasma viral burden during double or triple combination therapy in clinical practice [Abstract 421]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
22. 22 Hecht FM, Colfax G, Swanson M, Chesney JA. Adherence and effectiveness of protease inhibitors in clinical practice [Abstract 151]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
23. 23 Hertogs K, Mellors JW, Schel P, Van Cauwenberghe A. Larder B, Kemp S, et al. Patterns of cross-resistance among protease inhibitors in 483 clinical HIV-1 isolates [Abstract 395]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
24. 24 Johnson M for the European Viracept Clinical Trial Group. Comparison of BID and TID dosing of VIRACEPT® (nelfinavir, NFV) in combination with stavudine (d4T) and lamivudine (3TC) [Abstract 373]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
25. 25 Keruly JC, Chaisson RE, Moore RD. Diabetes and hyperglycemia in patients receiving protease inhibitors [Abstract 415]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
26. 26 Kost R, Cao Y, Vesanen M, Talal A, Hurley A, Schluger R, et al. Combination therapy with abacavir (1592), 141W94, and AZT/3TC in subjects acutely and chonically infected with HIV [Abstract 363]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
27. 27 Kravcik S, Farnsworth A, Patick A, Duncan I, Hawley-Foss N. Anderson R, et al. Long-term follow-up of combination protease inhibitor therapy with nelfinavir and saquinavir (soft gel) in HIV infection [Abstract 394-C]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
28. 28 Kuritzkes DR, Marschner IC, Johnson VA, Bassett RL, Eron JJ, Fischl MA, et al. A randomized, double-blind, placebo-controlled trial of lamivudine (3TC) in combination with zidovudine (ZDV), stavudine (d4T), or didanosine (ddI) in treatment naïve patients [Abstract 1]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
29. 29 Lal R, Hsu A, Granneman GR, El-Shourbagy T, Johnson M. Lam W, et al. Multiple dose safety, tolerability and pharmacokinetics of ABT-378 in combination with ritonavir [Abstract 647]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
30. 30 Lawrence J, Schapiro J, Winters M, Montoya J, Zolopa A, Pesano R, et al. Salvage therapy with indinavir plus nevirapine in patients previously treated with two other protease inhibitors and multiple reverse transcriptase inhibitors [Abstract 422]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
31. 31 Lori F, Jessen H, Clerici M, Lieberman J, Lisziewicz J, Right S, et al. Consistent, sustained HIV suppression without rebound by hydroxyurea, ddI, and a protease inhibitor prevents loss of immunological functions [Abstract 655]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
32. 32 Mellors J, Lederman M, Haas D. Horton J, Haubrich R, Stanford J, et al. Antiretroviral effects of therapy combining abacavir (1592) with HIV protease inhibitors (Pis) [Abstract 4]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
33. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Mcd 1997; 126 : 946-54.
34. 34 Moorman A, Delaney K, Palella F, Ashman D and the HIV Outpatient Study Group. Recent patterns of antiretroviral therapy and clinical response in ambulatory HIV patients [Abstract 144]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
35. 35 Opravil M, on behalf of the SPICE study team. Study of Protease Inhibitor Combination in Europe (SPICE): Saquinavir soft gelatin capsule and nelfinavir in HIV-infected individuals [Abstract 394-B]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
36. 36 Raboud JM, Montaner JSG, Conway B, Rae S, Reiss P, Vella S. et al. Suppression of plasma viral below 20 copies/mL is needed to achieve a long term antiretroviral response. AIDS (in press 1998).
37. 37 Rozenbaum W, Adda N, Wirbel E, Hadacek B, Schneider V, Costagliola D. Predictors and incidence of failure in 500 advanced stage HIV patients treated with indinavir [Abstract 420]. 5th Conference on Retroviruses and Opportunistic-Infections; 1998.
38. 38 Rutschmann OT, Opravil M, Iten A, Malinverni R, Vernazza P, Bucher H, et al. ddI + d4T +/-hydroxyurea for HIV-1 infection [Abstract 656]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
39. 39 Shaefer M, Shaker-Irwin L, Maude C, Williams V, Morales D, Thommes J, et al. Progression of disease in the Pacific Oaks Population Study (POPS) since the introduction of protease inhibitors and use of highly active antiretroviral therapy [Abstract 192]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
40. 40 Sommadossi JP, Zhou XJ, Moore J, Havlir DV, Friedland G, Tierney C, et al. Impairment of stavudine (d4T) phosphorylation in patients receiving a combination of zidovudine (ZDV) and d4T (ACTG 290) [Abstract 3]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.
41. 41 Workman C, Mussen R, Sullivan J. Salvage therapy using six drugs in heavily pretreated patients [Abstract 426]. 5th Conference on Retroviruses and Opportunistic Infections; 1998.